Ligand Pharmaceuticals (LGND) Surges 56% in 2026: How This Biotech Royalty Model Outperforms Traditional Pharma
Understanding Ligand Pharmaceuticals’ Unique Business Model Ligand Pharmaceuticals (LGND) has emerged as one of the standout performers in the life sciences sector, posting an impressive 56% gain year-to-date in 2026. Unlike traditional pharmaceutical companies that invest billions into research and development to bring drugs to market, Ligand operates on a fundamentally different model: it funds … Read more

